ICCB280 是一种C/EBPα诱导剂，通过激活 C/EBPα 并影响其下游靶点，具有终末分化、增殖停滞和凋亡的抗白血病特性。

ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis.

ICCB280 (10 μM; 2-8 d) increases the C/EBPα expression (mRNA and protein) and modulates its target genes in HL-60 cells.ICCB280 (0.1-50 μM; 48 h) suppresses the HL-60 cell growth, with an IC50 of 8.6 μM[1].

2041072-41-5

C23H18N2O4

386.407

DMSO:85mg/mL (219.98mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years